Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023
July 27 2023 - 4:30PM
Nyxoah to
Release Second
Quarter 2023 Financial
Results on August
8,
2023
Mont-Saint-Guibert, Belgium –
July 27,
2023,
10:30pm
CET /
4:30pm
ET – Nyxoah SA
(Euronext Brussels/Nasdaq:
NYXH) (“Nyxoah” or the “Company”), a medical technology
company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today
announced that the Company will release financial results for the
second quarter of 2023 on Tuesday, August 8, 2023, after market
close. Company management will host a conference call to discuss
financial results that day beginning at 10:30pm CET / 4:30pm
ET.
A webcast of the call will be accessible via the
Investor Relations page of the Nyxoah website or through this link:
Nyxoah's Q2 2023 earnings call webcast. For those not planning to
ask a question of management, the Company recommends listening via
the webcast.
If you plan to ask a question, please use the
following link: Nyxoah’s Q2 2023 earnings call. After registering,
an email will be sent, including dial-in details and a unique
conference call access code required to join the live call. To
ensure you are connected prior to the beginning of the call, the
Company suggests registering a minimum of 10 minutes before the
start of the call.
The archived webcast will be available for
replay shortly after the close of the call.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Following the positive outcomes of the BETTER SLEEP study, Nyxoah
received CE mark approval for the expansion of its therapeutic
indications to Complete Concentric Collapse (CCC) patients,
currently contraindicated in competitors’ therapy. Additionally,
the Company is currently conducting the DREAM IDE pivotal study for
FDA and U.S. commercialization approval.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Contacts:NyxoahDavid
DeMartino, Chief Strategy Officerdavid.demartino@nyxoah.com+1 310
310 1313
- ENGLISH_Q2 2023 Earnings Call Save-the-Date
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Apr 2024 to May 2024
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From May 2023 to May 2024